Article
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.
Molecular cancer therapeutics - 1 Jul 2010
Garon Edward B, Finn Richard S, Hosmer Wylie, Dering Judy, Ginther Charles, Adhami Shahriar, Kamranpour Naeimeh, Pitts Sharon, Desai Amrita, Elashoff David, French Tim, Smith Paul, Slamon Dennis J
Abstract excerpt
Selumetinib (AZD6244; ARRY-142886) is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK) 1 and 2 currently in clinical development. We evaluated the effects of selumetinib in 31 human breast cancer cell lines and 43 human non-small cell lung cancer (NSCLC)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.